Zimmermann K, Roggo S, Kragten E, Fürst P, Waldmeier P
Novartis Pharma Inc., Basel/Switzerland.
Bioorg Med Chem Lett. 1998 May 19;8(10):1195-200. doi: 10.1016/s0960-894x(98)00188-7.
Immobilized compounds for BIAcore studies and affinity precipitation as well as a fluorescent-labeled compound were prepared in order to identify the molecular target of the anti-apoptotic, neurorescuing compound CGP 3466 (N-methyl-N-propargyl-10-aminomethyl-dibenzo[b,f]oxepin).
